Last updated: September 4, 2026
Dapagliflozin has the strongest commercial trajectory of the three ingredients, driven by type 2 diabetes, heart failure, and chronic kidney disease indications. Metformin hydrochloride is a mature, commoditized generic with high volume but limited pricing power. Saxagliptin hydrochloride is in structural decline because DPP-4 inhibitors face competition from SGLT2 inhibitors, GLP-1 receptor agonists, and low-cost generic alternatives.
The commercial ranking is clear:
| Ingredient |
Primary commercial product |
Market position |
Financial trajectory |
| Dapagliflozin |
Farxiga/Forxiga, Xigduo/Xigduo XR |
Growth product across diabetes, heart failure, and kidney disease |
Strong growth through the mid-2020s, followed by U.S. erosion after generic entry |
| Metformin hydrochloride |
Generic metformin, Glucophage legacy brand |
First-line, high-volume, low-price therapy |
Stable unit demand, declining or flat value |
| Saxagliptin hydrochloride |
Onglyza, Kombiglyze/Kombiglyze XR |
Mature DPP-4 inhibitor |
Declining branded revenue and increasing generic pressure |
What is driving the dapagliflozin market?
Dapagliflozin has expanded beyond glucose control. Its value proposition now rests on cardiovascular and renal outcomes, not only hemoglobin A1c reduction.
Dapagliflozin indications and market expansion
The FDA approved Farxiga for type 2 diabetes in 2014. Later approvals expanded its use to reduce hospitalization for heart failure and to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease. The FDA also approved Farxiga for heart failure with reduced or preserved ejection fraction populations, broadening use beyond diabetes treatment (U.S. Food and Drug Administration, 2023a).
This indication expansion materially improved the product’s market economics:
| Market driver |
Commercial effect |
| Type 2 diabetes |
Established initial prescriber base |
| Heart failure |
Added cardiology and hospital-based prescribing |
| Chronic kidney disease |
Added nephrology and primary-care demand |
| Cardiovascular and renal outcome data |
Supported guideline adoption and reimbursement |
| Oral once-daily administration |
Improved positioning against injectable GLP-1 therapies |
| Combination use with metformin and other agents |
Increased treatment-line flexibility |
The principal competitive products are empagliflozin, marketed as Jardiance by Boehringer Ingelheim and Eli Lilly, and other SGLT2 inhibitors including canagliflozin and ertugliflozin. Dapagliflozin and empagliflozin have the broadest cardiovascular and renal commercial positioning.
How large are Farxiga and Forxiga sales?
AstraZeneca reported Farxiga/Forxiga product sales of approximately $5.98 billion in 2023, making it one of the company’s largest growth products (AstraZeneca, 2024). The sales increase reflected higher demand in the United States and international markets, wider heart failure use, and chronic kidney disease adoption.
Dapagliflozin sales have benefited from a shift in prescribing economics. Physicians increasingly use SGLT2 inhibitors for patients with cardiovascular or renal risk even when glucose lowering is not the primary treatment objective. That expands the addressable market beyond the traditional diabetes population.
The major financial risks are U.S. generic entry, price concessions to payers, and competition from empagliflozin. The product also faces treatment substitution from GLP-1 receptor agonists in patients prioritizing weight loss and from other SGLT2 inhibitors in heart failure and kidney disease.
What is the market trajectory for metformin hydrochloride?
Metformin hydrochloride is the most mature ingredient in the group. It remains a standard first-line therapy for type 2 diabetes because of its low cost, long clinical history, oral administration, and broad guideline support.
Metformin is sold as immediate-release and extended-release tablets, oral solutions, and combination products. Major combinations include dapagliflozin/metformin, saxagliptin/metformin, sitagliptin/metformin, and empagliflozin/metformin.
Why does metformin have high volume but limited revenue?
Metformin’s commercial profile is dominated by generic competition. Multiple manufacturers produce the active pharmaceutical ingredient and finished dosage forms. Retail prices for common generic tablets are low, and government and commercial formularies generally place metformin in the lowest-cost tiers.
| Metric |
Metformin hydrochloride profile |
| Demand |
High and persistent |
| Average price |
Low |
| Generic competition |
Extensive |
| Switching risk |
Low because clinical familiarity is high |
| Brand pricing power |
Minimal |
| Revenue growth potential |
Limited without combination or differentiated delivery |
The 2020-2021 extended-release contamination episode involving unacceptable levels of N-nitrosodimethylamine led to recalls and temporary supply disruption for certain products. It did not eliminate metformin’s long-term role, but it increased regulatory scrutiny of manufacturing controls and analytical testing (U.S. Food and Drug Administration, 2020).
The financial trajectory for metformin should be measured through prescription volume, active pharmaceutical ingredient demand, and combination-product sales rather than branded-drug revenue. No single company captures the total metformin market because sales are fragmented across generic manufacturers.
What manufacturing barriers affect metformin?
Metformin has limited composition-of-matter protection and low technical barriers for standard tablets. The principal barriers are manufacturing scale, quality-system compliance, supply-chain reliability, and regulatory control of impurities.
Extended-release formulations create more technical differentiation than immediate-release tablets. Formulation patents may protect release matrices, excipient systems, or combination products, but these protections generally do not restore strong pricing power for the underlying ingredient.
What is the commercial outlook for saxagliptin hydrochloride?
Saxagliptin is a DPP-4 inhibitor that was commercialized primarily through Onglyza and Kombiglyze XR. AstraZeneca acquired the global rights to saxagliptin from Bristol-Myers Squibb in 2009. The transaction transferred commercial responsibility for Onglyza and related products to AstraZeneca (AstraZeneca, 2009).
Saxagliptin’s market position weakened as treatment guidelines and prescribing behavior shifted toward medicines with demonstrated cardiovascular, renal, or weight-loss advantages.
Why has saxagliptin declined relative to dapagliflozin?
DPP-4 inhibitors remain useful because they are oral, generally weight-neutral, and associated with relatively low hypoglycemia risk. Their limitations are commercial:
- They provide less weight loss than GLP-1 receptor agonists.
- They lack the renal and heart-failure differentiation associated with SGLT2 inhibitors.
- They face extensive competition from sitagliptin, linagliptin, and generic DPP-4 products.
- They usually have weaker payer positioning than low-cost metformin or outcome-driven SGLT2 therapies.
The SAVOR-TIMI 53 trial identified an increased risk of hospitalization for heart failure with saxagliptin compared with placebo, although the trial did not show a significant increase in the primary composite cardiovascular endpoint (Scirica et al., 2013). The finding has affected clinical perception and can influence formulary preference in patients with heart-failure risk.
What is the financial trajectory of Onglyza?
Onglyza has moved from a branded growth product to a mature or declining product. AstraZeneca has not reported saxagliptin as a major standalone growth franchise in the manner of Farxiga. Financial pressure comes from:
- Brand aging and loss of exclusivity;
- Generic DPP-4 competition;
- Substitution by SGLT2 and GLP-1 therapies;
- Limited use in heart-failure patients;
- Reduced willingness among payers to pay a premium for a DPP-4 inhibitor.
Kombiglyze XR has an additional commercial limitation: it combines a declining DPP-4 inhibitor with a generic metformin component. The fixed-dose combination improves adherence for some patients but does not create durable pricing power once the principal saxagliptin protection erodes.
How do the three ingredients compare by therapeutic class?
| Attribute |
Dapagliflozin |
Metformin hydrochloride |
Saxagliptin hydrochloride |
| Drug class |
SGLT2 inhibitor |
Biguanide |
DPP-4 inhibitor |
| Main value driver |
Cardiorenal outcomes and glucose control |
Low-cost glycemic control |
Oral glucose lowering with low hypoglycemia risk |
| Weight effect |
Modest weight loss |
Weight neutral or modest loss |
Generally weight neutral |
| Heart-failure positioning |
Strong |
Not a primary differentiator |
Caution because of heart-failure signal |
| Kidney-disease positioning |
Strong |
Limited by renal function restrictions |
Limited |
| Generic exposure |
Increasing |
Extensive |
Increasing |
| Commercial growth |
High before generic erosion |
Volume-stable, value-limited |
Declining |
| Strategic role |
Growth franchise |
Foundation therapy |
Mature adjunctive therapy |
What patents protect dapagliflozin, metformin, and saxagliptin?
The patent estates differ substantially. Metformin has little meaningful composition-of-matter protection, while dapagliflozin and saxagliptin were protected by compound, formulation, and combination patents.
Dapagliflozin patent estate
Dapagliflozin was protected by early SGLT2 inhibitor patents covering C-aryl glucoside compounds, including U.S. Patent No. 6,515,117. The core U.S. term expired around 2020, subject to patent-term adjustment and pediatric exclusivity considerations. AstraZeneca also relied on later patents covering crystalline forms, formulations, combinations, and methods of treatment.
The commercial importance of the later estate is higher than the core compound patent because later patents can delay or complicate generic launch even after the original compound term expires. Generic applicants must address the Orange Book patents listed for the specific reference product and dosage form.
Saxagliptin patent estate
Saxagliptin was protected by compound patents including U.S. Patent No. 7,951,400. The principal protection reached the mid-2020s, with possible adjustments depending on the patent and product. Later patents covered formulations and combinations with metformin.
The saxagliptin estate is commercially weaker than the dapagliflozin estate because the underlying therapeutic market has less growth potential. A patent dispute can preserve revenue for a period, but it cannot reverse the broader shift away from DPP-4 inhibitors.
Metformin patent estate
Metformin hydrochloride’s original composition-of-matter protection has long expired. Current protection, where present, generally relates to:
- Extended-release delivery systems;
- Fixed-dose combinations;
- Specific excipient matrices;
- Manufacturing processes;
- Tablet coatings or release profiles.
These patents can protect a product presentation but do not create durable exclusivity for immediate-release metformin hydrochloride.
What is the FDA and Orange Book status of these products?
Farxiga, Onglyza, Xigduo XR, and Kombiglyze XR were approved under the FDA’s new drug application pathway. Generic versions are generally submitted through abbreviated new drug applications, which rely on the reference product’s safety and efficacy findings.
The FDA Orange Book identifies patents and regulatory exclusivity associated with approved reference products. The relevant legal analysis must distinguish between:
- The active ingredient;
- The specific dosage form;
- Combination-product claims;
- Method-of-use patents;
- Formulation patents;
- Patent-term adjustment;
- Pediatric exclusivity;
- Paragraph IV certifications.
A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The filing of a compliant Paragraph IV notice can trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman Act.
Are biosimilar risks relevant?
No. Dapagliflozin, metformin hydrochloride, and saxagliptin hydrochloride are chemically synthesized small molecules. They face generic, not biosimilar, competition. The relevant entry pathways are ANDAs, paragraph IV challenges, authorized generics, and settlement agreements.
Which companies are challenging the markets?
The competitive set differs by ingredient.
Dapagliflozin competitors
The principal competitors include:
- Boehringer Ingelheim and Eli Lilly, with empagliflozin;
- Johnson & Johnson, with canagliflozin;
- Merck and Pfizer, with ertugliflozin;
- Multiple generic manufacturers pursuing dapagliflozin products.
Empagliflozin has the strongest direct competitive position because it also has major heart-failure and kidney-disease indications.
Metformin competitors
Competition is fragmented across generic manufacturers, including large global and regional suppliers. The main competitive variable is manufacturing cost and supply reliability rather than clinical differentiation.
Saxagliptin competitors
Saxagliptin competes with:
- Merck’s sitagliptin;
- Boehringer Ingelheim’s linagliptin;
- Generic DPP-4 inhibitors;
- SGLT2 inhibitors;
- GLP-1 receptor agonists;
- Low-cost sulfonylureas and metformin-based regimens.
The competitive threat is therefore broader than a direct molecule-to-molecule comparison.
What generic entry risks exist?
| Ingredient |
Generic-entry risk |
Likely commercial effect |
| Dapagliflozin |
High as listed and later patents expire or are challenged |
Rapid U.S. price erosion, followed by volume retention and payer substitution |
| Metformin hydrochloride |
Already established |
Persistent low prices and fragmented market share |
| Saxagliptin hydrochloride |
High because of aging brand and declining demand |
Steep branded-revenue decline and limited ability to defend price |
Dapagliflozin is likely to retain substantial clinical demand after generic entry because it has multiple indications and guideline support. The product’s price, however, should decline materially as generic suppliers enter.
Saxagliptin faces a less favorable post-exclusivity profile. Generic entry will occur into a market already losing share to newer classes. That creates greater risk of volume displacement and lower branded persistence.
Metformin’s generic market is already mature. Future financial movement will depend more on supply concentration, raw-material costs, manufacturing compliance, and demand for combination products than on patent events.
What licensing deals affect the commercial landscape?
The most important transaction involving these ingredients was AstraZeneca’s 2009 acquisition of the global rights to saxagliptin from Bristol-Myers Squibb. The deal gave AstraZeneca control of Onglyza and related combination products (AstraZeneca, 2009).
Dapagliflozin was developed by AstraZeneca in collaboration with Bristol-Myers Squibb before AstraZeneca assumed full commercial control of the diabetes alliance. The product is now a core AstraZeneca franchise. Metformin is generally sourced through generic manufacturing and does not have a comparable centralized licensing structure.
What is the revenue exposure to loss of exclusivity?
Dapagliflozin has the highest absolute revenue exposure. Farxiga generated approximately $5.98 billion in 2023, so even moderate U.S. price erosion could reduce billions of dollars in annual revenue over the life of generic competition. AstraZeneca’s mitigation strategy rests on international growth, new indications, combination products, and continued use in cardiovascular and kidney disease.
Saxagliptin has lower absolute exposure but a weaker defense. The product lacks the same growth in non-diabetes indications, and its class is under competitive pressure. Revenue can fall rapidly after generic entry.
Metformin has minimal branded revenue exposure. The ingredient’s economic importance is large in aggregate, but the revenue is distributed among many manufacturers and is largely protected by volume rather than exclusivity.
How strong is each patent and commercial estate?
| Ingredient |
Patent strength |
Commercial strength |
Overall outlook |
| Dapagliflozin |
Moderate, with meaningful later-product and method patents |
Strong |
Best asset, but vulnerable to U.S. generic erosion |
| Metformin hydrochloride |
Weak for the active ingredient |
Strong volume, weak pricing |
Durable demand with low margins |
| Saxagliptin hydrochloride |
Moderate historically, weaker after product aging |
Weakening |
Declining franchise with high substitution risk |
Patent strength should not be confused with commercial durability. Dapagliflozin has the strongest commercial defense because the product has multiple indications. Saxagliptin may have enforceable patents, but the addressable market is less attractive. Metformin has little patent protection but remains commercially durable because physicians and payers continue to use it as a low-cost foundation therapy.
Key Takeaways
- Dapagliflozin is the only ingredient with a clear high-growth financial trajectory.
- Farxiga/Forxiga sales reached approximately $5.98 billion in 2023, supported by diabetes, heart-failure, and chronic-kidney-disease use.
- Dapagliflozin faces high U.S. generic-entry risk, but broad indications may preserve substantial post-generic volume.
- Metformin hydrochloride has strong demand but minimal pricing power and no meaningful composition-of-matter exclusivity.
- Saxagliptin hydrochloride is a mature, declining DPP-4 inhibitor with weaker differentiation than SGLT2 and GLP-1 therapies.
- The commercial risk for saxagliptin is not limited to patent expiry. Therapeutic substitution is already reducing its strategic value.
- None of the three ingredients presents a biosimilar risk because all are small-molecule drugs.
- Combination products can delay or complicate generic competition, but they do not eliminate the underlying erosion risk.
- The most important financial distinction is between dapagliflozin’s indication-driven growth, metformin’s volume-driven stability, and saxagliptin’s class-driven decline.
FAQs
Does dapagliflozin have stronger long-term value than saxagliptin?
Yes. Dapagliflozin has broader cardiovascular and renal indications, while saxagliptin remains primarily a glucose-lowering therapy with weaker differentiation.
Will generic metformin continue to grow in volume?
Demand is likely to remain high, but volume growth will depend on diabetes prevalence, combination-product use, and regional treatment guidelines. Revenue growth is constrained by very low prices.
Can a metformin combination patent block generic metformin?
No. A combination or extended-release patent may delay a specific product, but it generally does not block generic immediate-release metformin hydrochloride.
Why can dapagliflozin maintain value after generic entry?
Heart-failure and chronic-kidney-disease indications create a broader prescriber base and stronger clinical rationale than glucose lowering alone. Those factors can preserve demand even as prices decline.
Is saxagliptin still commercially relevant after patent expiry?
Yes, but mainly as a low-cost generic option. Its branded commercial value is limited by competition from sitagliptin, linagliptin, SGLT2 inhibitors, and GLP-1 receptor agonists.
References
AstraZeneca. (2009). AstraZeneca and Bristol-Myers Squibb announce agreement for saxagliptin and dapagliflozin diabetes alliance. AstraZeneca.
AstraZeneca. (2024). Annual report and Form 20-F for the year ended December 31, 2023. AstraZeneca.
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Leiter, L. A., Raz, I., & SAVOR-TIMI 53 Steering Committee and Investigators. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine, 369(14), 1317-1326.
U.S. Food and Drug Administration. (2020). FDA updates and press announcements on the NDMA impurity in metformin extended-release products. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2023a). Farxiga prescribing information. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2023b). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
U.S. Patent No. 6,515,117. (2003). C-aryl glucoside SGLT2 inhibitors.
U.S. Patent No. 7,951,400. (2011). Beta-amino tetrahydroimidazo[1,2-a]pyrazine compounds and methods of use.
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.
